Evaluation of HALP Score in Preeclampsia

NCT05816044 | Completed

• 1 other identifier: 67
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Preeclampsia is a serious condition that can occur during pregnancy and can pose problems for both the mother and the baby. It occurs in approximately 2-8% of all pregnancies globally and is caused by issues with blood vessels, leading to elevated blood pressure and other related health concerns. Additionally, insufficient nutrition and inflammation within the mother's body may contribute to the development of preeclampsia. The HALP score serves as a tool to assess various elements within the blood, indicating inflammation or inadequate nutrition. Although it has been utilized in other medical contexts, its application during pregnancy remains limited. The HALP score has been employed to predict the emergence of ailments such as heart disease and cancer. Given that preeclampsia can stem from inflammation and poor nutrition, the potential of the HALP score in predicting the likelihood of preeclampsia during pregnancy is being examined through research.

Conditions

Pre-Eclampsia

Keywords

preeclampsia; HALP score

Outcome Measures

Primary Outcomes (1)

• evaluate the HALP score in preeclamptic and healty pregnant woman

  The HALP score, which comprises Hemoglobin, Albumin, Lymphocyte, and Platelet parameters, is a useful tool for healthcare professionals to evaluate the nutritional and inflammatory status of a patient. Higher HALP scores are indicative of better immune-nutritional function, whereas lower scores suggest poorer immune-nutritional status. Thus, the HALP score provides valuable prognostic information that can guide treatment decisions and risk stratification for patients with various medical conditions. Currently, there is no standardized or universally accepted cutoff for the HALP score to predict specific outcomes. The optimal threshold for the HALP score is disease-specific and largely dependent on the study. This is based on the available literature.

  From January 2021 to January 2023, examination findings and medical tests of pregnant women diagnosed with preeclampsia, as well as healthy pregnant women, will be retrospectively evaluated by utilizing data documented by scanning patient records.

Study Arms (2)

preeclamptic pregnant woman

healty preagnant woman

Eligibility Criteria

• Age: 18 Years - 44 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

This study is a case-control retrospective study. Pregnant women between the ages of 18-44 who were diagnosed with preeclampsia and healthy pregnant woman in our clinic and whose follow-up and birth were in our hospital

You may qualify if:

• in preeclampsia group
• Having a singleton pregnancy.
• Pregnant women diagnosed with preeclampsia according to the American College of Obstetricians and Gynecologists (ACOG) 2020 gestational hypertension and preeclampsia bulletin criteria.
• Pregnant women who do not have a systemic inflammatory disease other than preeclampsia
• Pregnant women whose delivery and postpartum follow-up are in our clinic
• In the Control Group
• Having a singleton pregnancy
• Pregnant women who have no history or signs of systemic disease
• Pregnant women who have not found any maternal or fetal abnormality in the pregnancy follow-up
• Pregnant women whose delivery and postpartum follow-up are in our clinic

You may not qualify if:

• Multiple gestation pregnancies
• Known chronic or systemic disease (hypo or hyperthyroidism, diabetes, chronic hypertension, heart diseases, hyperlipidemia, chronic liver failure, acute or chronic kidney failure, etc.)
• Unknown pregnancy follow-up or fetal or maternal abnormalities detected during follow-up pregnant women
• Pregnant women whose delivery or postpartum follow-up is outside of our clinic

Sponsors & Collaborators

• Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization: lead

Study Sites (1)

Prof. Dr. Cemil Taşcıoğlu City Hospital

Istanbul, 34384, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: medical doctor

Study Record Dates

• First Submitted: April 1, 2023
• First Posted: April 18, 2023
• Study Start: February 22, 2023
• Primary Completion: May 22, 2023
• Study Completion: July 15, 2023
• Last Updated: August 29, 2023

Record last verified: 2023-08

Locations

TU (1)